

劉良



職稱：講座教授，榮譽校長，重點實驗室主任
學院/部門：中藥質量研究國家重點實驗室
電郵地址：lliu@must.edu.mo
電話：(853) 8897-2869

教學科目：中醫內科學、藥理實驗方法學(DCTZ02, DCWZ16, ME1003)

研究方向：臨床中藥學、中藥分子藥理、抗關節炎與抗癌創新藥物、中藥質量控制技術與方法

劉良教授現任澳門科技大學校長、講座教授、中藥質量研究國家重點實驗室(澳門科技大學)主任，兼任世界衛生組織傳統醫學項目顧問、國際標準組織 ISO/TC249 技術委員會委員及中藥標準化工作組召集人、國家重大基礎研究計劃(973 計畫)中醫理論專項專家組成員、國家自然科學基金特邀研究項目審評專家、國家中醫藥管理局國際合作交流專家諮詢委員會成員、世界中醫藥學會聯合會專家諮詢委員會副主席及教育專業委員會副主任委員、中國免疫學會中醫藥免疫分會副會長、澳門科學技術委員會委員、內地與澳門科技合作委員會委員、香港衛生署榮譽顧問、香港中醫藥研究及發展委員會委員、香港基層醫療改革專責小組成員、香港食物及衛生局研究項目審評專家、香港創新科技署知識財產權檢討委員會成員等學術和社會兼職和社會公職。作為專家委員會主席，劉教授主持通過了《世界衛生組織亞太區傳統醫學 2020 發展策略》，現正在實施中。劉教授是中藥全球化聯盟創盟成員及執行委員之一，亦擔任國內外十多種學術期刊的編輯委員會成員，及中國中醫科學院客座研究員、廣州中醫藥大學和湖南中醫藥大學客座教授。

劉教授 1990 年畢業於廣州中醫藥大學，獲醫學博士學位(中西醫結合研究方向)。1992 年赴德國漢諾威醫學院分子藥理研究所及愛爾蘭根-紐倫堡大學馬普研究協會(德國科學院)風濕病與免疫研究所擔任訪問學者，從事中藥抗炎免疫藥理研究。回國後於 1997 年出任廣州中醫藥大學副校長、教授、博士生導師。2000 年 8 月透過香港“輸入內地優秀人才計畫”前往香港工作，出任浸會大學中醫藥學院常務副院長及教授，2001 年 1 月升任為該院奠基院長，任職至 2011 年 6 月止。劉教授 2006 年成為香港浸會大學終身教授，2007 年 4 月晉升為該校終身講座教授。2009 年創立岑堯寬岑碧泉紀念癌癥炎癥研究中心並兼任主任。2011 年 7 月起，劉教授辭任香港浸會大學職位，出

任澳門科技大學副校長，負責全校的研究及拓展事務，2013年1月升任該校校長。

劉教授學貫中西醫學，是知名的中醫藥研究專家，主要從事中藥抗炎免疫藥理和抗關節炎新藥研究。他承擔或參與了國家自然科學基金委員會、國家科技部重大基礎研究項目(973 計畫和攀登計畫)、國家重大新藥創製計畫、廣東省科學基金、香港研究資助局、澳門特別行政區科學技術發展基金、香港創新科技署、香港賽馬會中藥研究院等政府機構資助的研究項目 40 多項，在國內外學術刊物及會議發表研究報告逾 340 篇，包括 Nature, Cell Death & Diseases, Briefings in Bioinformatics, Chromatography A, Pharmaceutical Research, J Cellular Biochemistry, BBRC 等國際知名學術期刊，在國內外學術會議作特邀報告 70 多次。獲得各種獎勵及榮譽稱號 18 項，包括國家科技進步獎二等獎 2 項及三等獎 1 項，部(省)級科研成果獎 5 項。獲美國和中國國家專利局專利授權 5 項；主編或參與編寫出版學術專著及教材 18 部，包括一套三冊的中醫英文教科書《Essentials of Chinese Medicine》(中醫藥精華)，由世界著名出版機構 Springer 出版發行，被世界許多知名教研機構和圖書館收藏；主編發行《中藥臨床安全用藥》專著，為現今港澳地區眾多註冊中醫師的參考用書。1998 年，國家勞動人事部授予他「有突出貢獻的中青年專家」稱號，1999 年入選國家教育部「跨世紀優秀人才計劃」。2009 年，加拿大特許管理學院授予他榮譽院士資格，以表彰他致力推動中醫藥國際化和標準化的突出貢獻。劉教授亦曾擔任國家科技部新藥研究與開發專家委員會委員、中華中醫藥學會理事，中國中西醫結合學會中藥專業委員會副主任委員、國家中醫藥管理局及廣東省科技項目及成果評審專家、香港賽馬會中藥研究院董事局董事、香港中醫藥管理委員會委員及多個中醫藥專業社團的榮譽顧問等。

學歷

- | | |
|-------------|--|
| 1992 - 1994 | 德國漢若威醫學院及馬普風濕病與免疫研究所 / 抗炎免疫藥理研究 / 訪問學者 |
| 1991 - 1992 | 上海外國語大學 / 德語培訓 |
| 1987 - 1990 | 廣州中醫藥大學 / 中西醫結合 / 博士學位 |
| 1983 - 1985 | 廣州中醫藥大學 / 中西醫結合 / 碩士學位 |
| 1978 - 1982 | 廣州中醫學院 / 中醫學 / 學士學位 |
| 1975 - 1977 | 常德地區衛生學校 / 西醫學 / 醫士 |

工作履歷

- | | |
|------------------|--|
| 2021.1-現職 | 澳門科技大學 / 榮譽校長、講座教授
中藥質量研究國家重點實驗室 / 主任 |
| 2013.1 – 2020.12 | 澳門科技大學 / 校長、講座教授 |

中藥質量研究國家重點實驗室 / 主任
 2011.7 - 2012.12 澳門科技大學 / 副校長、講座教授
 中藥質量研究國家重點實驗室 / 主任
 2009.9 - 2011.6 香港浸會大學 / 中醫藥學院 / 院長、講座教授
 香港浸會大學 / 岑堯寬岑碧泉紀念癌症炎症研究中心 / 主任
 2007.4 - 2009.8 香港浸會大學 / 中醫藥學院 / 院長、講座教授
 2001.1 - 2007.3 香港浸會大學 / 中醫藥學院 / 院長、教授
 2000.8 - 2000.12 香港浸會大學 / 中醫藥學院 / 常務副院長、教授
 1997.9 - 2000.7 廣州中醫藥大學 / 副校長、教授
 1996.6 - 1997.8 廣州中醫藥大學 / 校長助理、副教授
 1991.8 - 1996.5 廣州中醫藥大學 / 副教授
 1990.8 - 1991.7 廣州中醫學院 / 講師
 1986.1 - 1987.8 廣州中醫學院 / 講師

學術成果

近年發表的主要 SCI 期刊論文: (* Corresponding author)

1. Fan XX, Pan HD, Li Y, Guo RJ, Leung Elaine LH, Liu L*. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity. *Pharmacology and Therapeutics*. June 2018.
2. Li RZ, Fan XX, Duan FG, Jiang ZB, Pan HD, Luo LX, Zhou YL, Li Y, YaoXJ, Leung EL*, Liu L*. Proscillaridin A induces apoptosis and suppresses non-small-cell lung cancer tumor growth via calcium-induced DR4 upregulation. *Cell Death Dis*. 2018 Jun 13;9(6):696.
3. Pan HD, Guo RJ, Zhu J, Wang Q, Ju YM, Xie Y, Zheng YF, Wang ZF, Li T, Liu ZQ, Lu LL, Li F, Tong B, Xiao L, Xu X, Li RZ, Yuan ZW, Yang HM, Wang J, Kristiansen K, Jia HJ* and Liu L*. A gene catalogue of the Sprague-Dawley rat gut metagenome. *GigaScience*, May, 2018.
4. Zhu GY, Yang J, Yao X, Yang X, Fu J, Liu X, Bai LP, Liu L, Jiang ZH. (±)-sativamides a and b, two pairs of racemic nor-lignanamide enantiomers from the fruits of cannabis sativa (hemp seed) [J]. *The Journal of organic chemistry*, 2018, 83 (4), pp 2376–2381.
5. Wang QQ, Xu JH, Li Y, Huang JM, Jiang ZB, Wang YW, Liu L, Leung EL, Yao XJ. Identification of a novel protein arginine methyltransferase 5 inhibitor in non-small cell lung cancer by structure-based virtual screening [J]. *Frontiers in pharmacology*, 2018, 9:173.
6. Wan HY, Chen JL, Zhu XZ, Liu L, Wang JF, Zhu XM. Titania-coated gold nano-bipyramids for blocking autophagy flux and sensitizing cancer cells to proteasome inhibitor-induced death [J]. *Advanced Science*, 2018, 5 (3):1700585.

7. Su XH, Li T, Liu ZQ, Huang QC, Liao KS, Ren RT, Lu LL, Qi XX, Wang MJ, Chen JY, Zhou H, Leung EL, Pan HD, Liu J, Wang H, Huang LF, Liu L*. Licochalcone activates keap1-nrf2 signaling to suppress arthritis via phosphorylation of p62 at serine 349 [J]. *Free Radical Biology and Medicine*, 2018, 115:471-483.
8. Liu XY, Yang KY, Wang MQ, Kwok JSL, Zeng X, Yang ZY, Xiao XJ, Lau CPY, Li Y, Huang ZM, Ba JG, Yim AK, Quyang CY, Ngai SM, Chan TF, Leung EL, Liu L, Liu ZG, Tsui SK. High-quality assembly of dermatophagoides pteronyssinus genome and transcriptome reveals a wide range of novel allergens [J]. *Journal of Allergy and Clinical Immunology*, 2018 Jan 2. pii: S0091-6749(17)33013-0.
9. Wu JJ, Guo ZZ, Zhu YF, Huang ZJ, Gong X, Li YH, Son WJ, Li XY, Lou YM, Zhu LJ, Lu LL, Liu ZQ, Liu L*. A systematic review of pharmacokinetic studies on herbal drug fuzi: Implications for fuzi as personalized medicine [J]. *Phytomedicine*, 2018, Mar 1. doi: 10.1016/j.phymed.2018.03.001
10. Chen TB, Zuo YH, Dong GT, Liu L*, Zhou H. An integrated strategy for rapid discovery and identification of quality markers in guanxin kangtai preparation using uhplc-tof/ms and multivariate statistical analysis [J]. *Phytomedicine*, 2018 Mar 6. doi: 10.1016/j.phymed.2018.03.005.
11. Leung EL, Luo LX, Liu ZQ, Wong VK, Lu LL, Xie Y, Zhang N, Qu YQ, Fan XX, Li Y, Huang M, Xiao DK, Huang J, Zhou YL, He JX, Ding J, Yao XJ, Ward DC, Liu L*. Inhibition of kras-dependent lung cancer cell growth by deltarasin: Blockage of autophagy increases its cytotoxicity [J]. *Cell death & disease*, 2018, 9 (2):216.
12. Fan XX, Leung EL, Xie Y, Liu ZQ, Zheng YF, Yao XJ, Lu LL, Wu JL, He JX, Yuan ZW, Fu J, Wei CL, Huang J, Xiao DK, Luo LX, Jiang ZB, Zhou YL, Kam RK, Liu L*. Suppression of lipogenesis via reactive oxygen species–ampk signaling for treating malignant and proliferative diseases [J]. *Antioxidants & redox signaling*, 2018, 28 (5):339-357.
13. Zhuo Y, Wu JL, Yan X, Guo MQ, Liu N, Zhou H, Liu L*, Li N*. Strategy for hepatotoxicity prediction induced by drug reactive metabolites using human liver microsome and online 2d-nano-lc-ms analysis [J]. *Analytical chemistry*, 2017, 89 (24):13167-13175.
14. Zhu MZ, Li N, Wang YT, Liu N, Guo MQ, Sun BQ, Zhou H, Liu L*, Wu JL*. Acid/salt/ph gradient improved resolution and sensitivity in proteomics study using 2d scx-rp lc–ms [J]. *Journal of proteome research*, 2017, 16 (9):3470-3475.
15. Yu J, Kong L, Zhang A, Han Y, Liu Z, Sun H, Liu L, Wang X. High-throughput metabolomics for discovering potential metabolite biomarkers and metabolic mechanism from the appswe/ps1de9 transgenic model of alzheimer’s disease [J]. *Journal of proteome research*, 2017, 16 (9):3219-3228.
16. Zhou H, Liu JX, Luo JF, Cheng CS, Leung EL, Li Y, Su XH, Liu ZQ, Chen TB, Duan FG, Dong Y, Zuo YH, Li C, Lio CK, Li T, Luo P, Xie Y, Yao XJ, Wang PX, Liu L*. Suppressing mpge-1 expression by sinomenine ameliorates inflammation and arthritis [J]. *Biochemical pharmacology*, 2017, 142:133-144.

17. Yuan ZW, Li YZ, Liu ZQ, Feng SL, Zhou H, Liu CX, Liu L*, Xie Y*. Role of tangeretin as a potential bioavailability enhancer for silybin: Pharmacokinetic and pharmacological studies [J]. *Pharmacological research*, 2018, 128:153-166.
18. Wu AG, Zeng W, Wong VK, Zhu YZ, Lo AC, Liu L*, Law BY*. Hederagenin and α -hederin promote degradation of proteins in neurodegenerative diseases and improve motor deficits in mptp-mice [J]. *Pharmacological research*, 2017, 115:25-44.
19. Wu JJ, Zhu YF, Guo ZZ, Lou YM, He SG, Guan Y, Zhu LJ, Liu ZQ, Lu LL*, Liu L*. Aconitum alkaloids, the major components of aconitum species, affect expression of multidrug resistance-associated protein 2 and breast cancer resistance protein by activating the nrf2-mediated signalling pathway. *Phytomedicine*, 2017 Dec 8. doi: 10.1016/j.phymed.2017.12.
20. Wang Y, Zhou C, Gao H, Li C, Li D, Liu P, Huang M, Shen X*, Liu L*. Therapeutic effect of cryptotanshinone on experimental rheumatoid arthritis through downregulating p300 mediated-stat3 acetylation [J]. *Biochemical pharmacology*, 2017, 138:119-129.
21. Wang QQ, Li Y, Xu JH, Wang YW, Leung EL, Liu L*, Yao XJ*. Selective inhibition mechanism of rvx-208 to the second bromodomain of bromo and extraterminal proteins: Insight from microsecond molecular dynamics simulations. *Scientific reports*, 2017, 7 (1):8857.
22. Wang JR, Gao WN, Grimm R, Jiang S, Liang Y, Ye H, Li ZG, Yau LF, Huang H, Liu J, Jiang M, Meng Q, Tong TT, Huang HH, Lee S, Zeng X, Liu L*, Jiang ZH*. A method to identify trace sulfated igg n-glycans as biomarkers for rheumatoid arthritis. *Nature communications*, 2017, 8 (1):631.
23. Luo LX, Li Y, Liu ZQ, Fan XX, Duan FG, Li RZ, Yao XJ, Leung EL, Liu L*. Honokiol induces apoptosis, G1 arrest, and autophagy in kras mutant lung cancer cells. *Frontiers in pharmacology*, 2017, 8:199.
24. Ren X, Chen L, Xie J, Zhang Z, Dong G, Liang J, Liu L, Zhou H, Luo P. Resveratrol ameliorates mitochondrial elongation via drp1/parkin/pink1 signaling in senescent-like cardiomyocytes [J]. *Oxidative medicine and cellular longevity*, 2017, 2017: 4175353.
25. Li X, Fan XX, Jiang ZB, Loo WT, Yao XJ, Leung EL*, Chow LW*, Liu L*. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting trxr and activating the egfr proteasomal degradation pathway. *Pharmacological research*, 2017, 115:45-55.
26. Law BY, Mok SW, Chen J, Michelangeli F, Jiang ZH, Han Y, Qu YQ, Qiu CL, Xu SW, Xue WW, Yao XJ, Javed MH, Coghi P, Liu L*. N-desmethyldauricine induces autophagic cell death in apoptosis-defective cells via ca²⁺ mobilization. *Frontiers in pharmacology*, 2017, 8:388.
27. Huang L, Dong Y, Wu J, Wang P, Zhou H, Li T, Liu L*. Sinomenine-induced histamine release-like anaphylactoid reactions are blocked by tranilast via inhibiting nf- κ b signaling. *Pharmacological research*, 2017, 125:150-160.

28. He F, Wang CJ, Xie Y, Cheng CS, Liu ZQ, Liu L*, Zhou H*. Simultaneous quantification of nine aconitum alkaloids in aconiti lateralis radix praeparata and related products using uhplc–qqq–ms/ms. *Scientific reports*, 2017, 7 (1):13023.
29. Dias IRDSR, Mok SW, Gordillo-Martínez F, Khan I, Hsiao WW, Law BY, Wong VK*, Liu L*. The calcium-induced regulation in the molecular and transcriptional circuitry of human inflammatory response and autoimmunity. *Frontiers in Pharmacology*, 2018, 8:962.
30. Wu WJ, Jia WW, Liu XH, Pan LL, Zhang QY, Yang D, Shen XY, Liu L, Zhu YZ. S-propargyl-cysteine attenuates inflammatory response in rheumatoid arthritis by modulating the nrf2-are signaling pathway. *Redox biology*, 2016, 10:157-167.
31. Wu J, Lin N, Li F, Zhang G, He S, Zhu Y, Ou R, Li N, Liu S, Feng L, Liu L, Liu Z, Lu L. Induction of p-glycoprotein expression and activity by aconitum alkaloids: Implication for clinical drug–drug interactions. *Scientific reports*, 2016, 6:25343.
32. Wong VK, Law BY, Yao XJ, Chen X, Xu SW, Liu L*, Leung EL*. Advanced research technology for discovery of new effective compounds from chinese herbal medicine and their molecular targets. *Pharmacological research*, 2016, 111:546-555.
33. Su X, Huang Q, Chen J, Wang M, Pan H, Wang R, Zhou H, Zhou Z, Liu J, Yang F, Li T*, Liu L*. Calycosin suppresses expression of pro-inflammatory cytokines via the activation of p62/nrf2-linked heme oxygenase 1 in rheumatoid arthritis synovial fibroblasts. *Pharmacological research*, 2016, 113:695-704.
34. Liu J, Tang J, Zuo Y, Yu Y, Luo P, Yao X, Dong Y, Wang P, Liu L*, Zhou H*. Stauroside b inhibits macrophage activation by inhibiting nf-kb and erk mapk signalling. *Pharmacological research*, 2016, 111:303-315.
35. Leung EL, Fan XX, Wong MP, Jiang ZH, Liu ZQ, Yao XJ, Lu LL, Zhou YL, Yau LF, Tin VP, Liu L*. Targeting tyrosine kinase inhibitor-resistant non-small cell lung cancer by inducing epidermal growth factor receptor degradation via methionine 790 oxidation. *Antioxidants & redox signaling*, 2016, 24 (5):263-279.
36. Huang Z, Huang Q, Ji L, Wang Y, Qi X, Liu L, Liu Z, Lu L. Epigenetic regulation of active Chinese herbal components for cancer prevention and treatment: A follow-up review [J]. *Pharmacological research*, 2016, 114:1-12.
37. Huang L, Pi J, Wu J, Zhou H, Cai J, Li T*, Liu L*. A rapid and sensitive assay based on particle analysis for cell degranulation detection in basophils and mast cells [J]. *Pharmacological research*, 2016, 111:374-383.
38. Feng S-L, Yuan Z-W, Yao X-J, Ma W-Z, Liu L, Liu Z-Q, Xie Y. Tangeretin, a citrus pentamethoxyflavone, antagonizes abcb1-mediated multidrug resistance by inhibiting its transport function [J]. *Pharmacological research*, 2016, 110:193-204.
39. Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, Wu X, Li J, Tang L, Li Y, Lan Z, Chen B, Li Y, Zhong H, Xie H, Jie Z, Chen W, Tang S, Xu X, Wang X, Cai X, Liu S, Xia Y, Li J, Qiao X, Al-Aama JY, Chen H, Wang L, Wu QJ, Zhang F, Zheng W, Li Y, Zhang

- M, Luo G, Xue W, Xiao L, Li J, Chen W, Xu X, Yin Y, Yang H, Wang J, Kristiansen K, Liu L, Li T, Huang Q, Li Y, Wang J. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment [J]. *Nature medicine*, 2015, 21 (8):895.
40. Yuan ZW, Leung EL, Fan XX, Zhou H, Ma WZ, Liu L*, Xie Y*. Quantitative evaluation of berberine subcellular distribution and cellular accumulation in non-small cell lung cancer cells by uplc–ms/ms [J]. *Talanta*, 2015, 144:20-28.
 41. Yang ZF, Leung EL, Liu L, Jiang ZH, Zhong N. Developing influenza treatments using traditional chinese medicine [J]. *Science*, 2015, 347 (6219):S35-S37.
 42. Wu AG, Wong VK, Zeng W, Liu L*, Law BY*. Identification of novel autophagic radix polygalae fraction by cell membrane chromatography and uhplc-(q) tof-ms for degradation of neurodegenerative disease proteins [J]. *Scientific Reports*, 2015, 5:17199.
 43. Lu LL, Liu XH, Leung EL, Wang Y, Shi J, Hu M, Liu L*, Liu ZQ*. The bioavailability barrier and personalized traditional chinese medicine [J]. *Science*, 2015, 350 (6262):S79-S81.
 44. Fan XX, Yao XJ, Xu SW, Wong VK, He JX, Ding J, Xue WW, Mujtaba T, Michelangeli F, Huang M, Huang J, Xiao DK, Jiang ZB, Zhou YL, Kam RK, Liu L*, Leung EL*. (z) 3, 4, 5, 4'-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level [J]. *Scientific reports*, 2015, 5:16348.
 45. Wang JR, Zhang H, Yau LF, Mi JN, Lee S, Lee KC, Hu P, Liu L*, Jiang ZH*. Improved sphingolipidomic approach based on ultra-high performance liquid chromatography and multiple mass spectrometries with application to cellular neurotoxicity [J]. *Analytical chemistry*, 2014, 86 (12):5688-5696.
 46. Leung EL, Wong VK, Jiang ZH, Li T, Liu L*. Integrated network-based medicine: The role of traditional chinese medicine in developing a new generation of medicine [J]. *Science*, 2014, 346 (6216):S16-S18.
 47. Law BY, Chan WK, Xu SW, Wang JR, Bai LP, Liu L*, Wong VK*. Natural small-molecule enhancers of autophagy induce autophagic cell death in apoptosis-defective cells [J]. *Scientific reports*, 2014, 4:5510.
 48. Wong VK, Li T, Law BY, Ma ED, Yip N, Michelangeli F, Law CK, Zhang M, Lam KY, Chan PL, Liu L*. Saikosaponin-d, a novel serca inhibitor, induces autophagic cell death in apoptosis-defective cells [J]. *Cell death & disease*, 2013, 4 (7):e720.
 49. Leung EL, Cao Z-W, Jiang Z-H, Zhou H, Liu L*. Network-based drug discovery by integrating systems biology and computational technologies [J]. *Briefings in bioinformatics*, 2012, 14 (4):491-505.
 50. Liu L*, Leung EL, Tian X. Perspective: The clinical trial barriers [J]. *Nature*, 2011, 480 (7378):S100-S100.

學術機構及社會任職

學術期刊任職

1. Journal of Chinese Medicine (English), 2012-Present
2. Journal of Traditional and Complementary Medicine (English), 2011-Present
3. Journal of Chinese Materia Medica, 2008-Present
4. Journal of Chinese Medicine Modernization, 2008-Present
5. Journal of Chinese Herbal Medicine (English), 2008-Present
6. Chinese J. of Integrative Western and Chinese Medicine (English), 2006-Present
7. Chinese Medicine (English), 2006-Present
8. Journal of Chinese Evidence-based Medicine, 2006-Present
9. Chinese J. of Natural Products, 2003-Present
10. Chinese J. of Immunology, 2002-Present
11. Chinese J. of Chinese Materia Medica, 2002-Present
12. J. of Guangzhou University of Traditional Chinese Medicine, 1999-2001
13. J. Hubei Integrated Chinese Medicine with Western Medicine, 1999-2001

學術及社會機構任職

1. Project Advisor, World Health Organization (WHO), 2003 - Present
2. Member, Expert Panel for WHO ICD-TM, 2008 – Present
3. Convener, Working Group One of ISO/TC249 on Traditional Medicine, 2011- Present
4. Member, Technical Committee for ISO/TC249 on Traditional Medicine, 2010 - Present
5. Member, Science and Technology Committee of Macau Special Administrative Region, 2013.1. – Present
6. Member, Committee for the Corporations between the Mainland and Macau on Science and Technology, 2013.1 – Present
7. Member, Expert Advisory Committee for Developing Overseas Collaboration in Chinese Medicine, State Administration in Chinese Medicine, 2011 – Present
8. Member, Expert Panel on the Chinese Medicine Project under the National 973 Research Scheme, 2012 - Present
9. Member, Expert Panel for the Assessment of Chinese Medicine Research, Natural Science Foundation of China, 1998 – Present
10. Vice-Chair of the Educational Committee, Federation of World Chinese Medicine Societies, 2006 - Present

11. Vice-Chair of the Advisory Expert Committee, Federation of World Chinese Medicine Societies, 2011 - Present
12. Vice-President of the Chinese Medicine and Immunology Association, China Immunology Society, 2005 - Present
13. Founding and Executive Member of the Consortium for Globalization of Chinese Medicine, 2003 - Present
14. Executive President, The Collaborative Centre of Science and Technology on Chinese Medicine for the Mainland, Taiwan, Hong Kong and Macau, 2011.12 - Present
15. Honorary Consultant, Department of Health of Hong Kong Special Administrative Region (HKSAR), 2011.6 - Present
16. Member, Working Group on Primary Care, Health and Medical Development Advisory Committee, HKSAR, 2008.10 - Present
17. Honorary Chairman, The Hong Kong Scientist Association, HKSAR, 2009.1 - Present
18. Distinguished Guest Researcher, Chinese Medical Academy of China, 2011.11 – Present
19. Distinguished Guest Professor, Guangzhou University of Chinese Medicine, 2011.11-Present
20. Distinguished Guest Professor, Hunan University of Chinese Medicine, 2007 - Present
21. Advisor, Hong Kong Idea Centre, 2010.3 – Present
22. Permanent Member, China Immunology Society, 2002 - Present
23. Member, China Pharmacological Society, 1994 - Present
24. International Chinese Medicine Society of Macau, 2001- Present
25. Member, Association of Integrative Chinese and Western Medicine, 2004 - Present
26. Chairman, Expert Panel Meeting for 2020 Strategy of Traditional Medicine in the West Pacific Region, Western Pacific Regional Office, WHO, 2011
27. Member, Grant Review Board, Health and Health Services Research Fund (HHSRF) and Research Fund for the Control of Infectious Diseases (RFCID), HKSAR, 2011. 2 - 2013
28. Member, Committee on Review of Intellectual Property Issues, Innovation and Technology Commission (ITC), HKSAR, 2010.11 - 2012.10
29. Member, Technical Committee, Hong Kong Jockey Club Institute of Chinese Medicine Limited, HKSAR, 2009.8 - 2011.11
30. Member, Council of Chinese Medicine of Hong Kong, 2008.9 – 2011.8
31. Directors of Hong Kong Jockey Club Institute of Chinese Medicine Limited, HKSAR, 2009.8- 2011.11
32. Standing Member, Standing Committee of the World Federation of Chinese Medicine Societies, 2007 – 2011.10
33. Guest PhD Candidate Supervisor at Tianjin University of Traditional Chinese Medicine,

2006-2011

34. Advisor and Co-Chair, Expert Panel for Establishment of Traditional Medicine Practice Guidelines, Western Pacific Regional Office, WHO, 2006-2007
35. Proof Reading Reviewer for International Basic Terms of Traditional Medicine, Western Pacific Regional Office, WHO, 2006
36. Member, Japanese Pharmaceutical Society, 2003-2006
37. Member, Association of Registered Chinese Medicine Practitioners, HKSAR, 2011-Present
38. Temporary Advisor for Establishment of Guidelines for Academic Education Guidelines, Western Pacific Regional Office, WHO, 2003
39. Academic Advisor, Association of Registered Chinese Medicine Practitioners, 2003-Present
40. Academic Advisor, Xinhua Association for Promotion of Chinese Medicine, 2002-Present
41. Chairman, The Liaison Group for Formulation of Guidelines on the Insurance of Sick Leave Certificates by Registered Chinese Medicine Practitioners, Practitioners Board of Chinese Medicine Council of Hong Kong, HKSAR, 2002 -2003
42. Member, Expert Committee on Regulation of Health Claims, Department of Health of Hong Kong, HKSAR, 2002-2003
43. Member of the Practitioners Board of Chinese Medicine Council of Hong Kong, HKSAR, 2002-2008
44. Member of the Expert Committee on New Drug Discovery, Ministry of Science and Technology of China, 1998-2001
45. Executive Member, Standing Committee of Guangdong Association of Traditional Chinese Medicine, Guangdong Province, China, 1998-2003
46. Standing Member, Standing Committee of Guangdong Chinese Medicine Society, 1998-2003
47. Deputy Chair, Sub-committee on Chinese Medicines, Chinese Association of Integrative Chinese and Western Medicine, 1998-2003
48. Standing Member, Guangzhou Association of Scientists and Technologists, Guangzhou, China, 1998-2001
49. Deputy-Director , Educational Program Development, Guangdong Province, China 1998-2001
50. Vice-President, Guangdong Association of Overseas Returned Scientists, Guangdong Province, China, 1998-2000
51. Standing Member, Standing Committee of the Chinese Association of Medicine-Doctorate Fellows, Beijing, China, 1997-2005

專業資格認證及獎項

獲獎及榮譽稱號選錄:

1. 中藥“三多”特徵的創新研究方法及其理論基礎，獲澳門自然科學獎(二等)，澳門特別行政區政府頒授，2014
2. 抗關節炎中藥製劑質量控制與活性評價方法的創新及產品研發，獲國家科技進步獎(二等)，中華人民共和國國務院頒授，2012
3. 脾虛證辨證論治的系列研究，獲國家科學技術進步獎(二等)，中華人民共和國國務院頒授，2000
4. 常用中藥材品種整理和質量研究--- 草豆蔻 肉豆蔻等八十三類中藥材的品種鑒定和質量研究，獲國家科技進步獎三等獎，中華人民共和國國務院頒授，1997
5. “有突出貢獻中青年專家”稱號，中華人民共和國勞動人事部頒授，1998
6. 入選“跨世紀優秀人才計劃”，中華人民共和國教育部頒授，1999
7. 抗關節炎中藥製劑質量控制與活性評價方法的創新與產品研發，獲李時珍醫藥創新獎，中華中醫藥學會頒授，2011
8. 加拿大特許管理學院榮譽院士，加拿大特許管理學院頒授，2009
9. 中醫藥治療類風濕關節炎的作用機理研究，獲廣東省科學技術獎勵(二等)，中國廣東省人民政府頒授，2006
10. 四君子湯益氣健脾藥效的物質基礎及其作用機理研究，獲廣東省科學技術獎勵(二等)中國廣東省人民政府頒授，2002
11. 引種栽培進口“南藥”藥材質量的評價，廣東省中醫藥科技進步獎(二等)，中國廣東省中醫藥管理局頒授，1998
12. “九五”期間“五個一科教興醫工程”學術與技術帶頭人，中國廣東省衛生廳頒授，1996
13. 獲廣東省優秀青年中醫和中西醫結合工作者稱號，中國廣東省中醫藥管理局頒授，1995
14. 健脾、清熱、化瘀中藥及其配伍抗潰瘍作用的實驗與臨床研究，獲廣東省中醫藥科學技術進步獎(一等)，中國廣東省中醫藥管理局，1994